natgillin/translations-raw huggingface dataset:
Given that 21 Member States control MDPV under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances, and that four Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
Tako kot ketamin in fenciklidin ima tudi metoksetamin disociativne lastnosti.
Methoxetamine is an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP).
Na voljo ni študij o oceni kronične in akutne toksičnosti, povezane z metoksetaminom, psihičnih in vedenjskih učinkih ter o možnostih za povzročanje odvisnosti.
Like ketamine and PCP, it has dissociative properties.
Iz opisov izkušenj na straneh uporabnikov je mogoče razbrati, da ima metoksetamin škodljive učinke, ki so podobni učinkom pri zastrupitvi s ketaminom.
There are no studies assessing the chronic and acute toxicity associated with methoxetamine, as well as its psychological and behavioural effects and dependence potential.
Ti učinki vključujejo slabost in hudo bruhanje, težave z dihanjem, napade, izgubo orientacije, tesnobnost, katatonijo, agresijo, halucinacije, paranojo in psihozo.
Self-reported experiences from user websites suggest adverse effects similar to ketamine intoxication.
Poleg tega akutne zastrupitve z metoksetaminom lahko vključujejo take učinke, kot jih imajo poživila (tresenje, tahikardijo in hipertenzijo), ter cerebralne simptome, ki niso običajni pri akutni zastrupitvi s ketaminom.
These include nausea and severe vomiting, difficulty in breathing, seizures, disorientation, anxiety, catatonia, aggression, hallucination, paranoia and psychosis.
Šest držav članic je v zvezi z metoksetaminom poročalo o 20 smrtnih primerih, pri katerih je bila prisotnost te snovi ugotovljena v vzorcih, odvzetih po smrti.
In addition, acute methoxetamine intoxications may include stimulant effects (agitation, tachycardia and hypertension) and cerebral features, which are not expectable with acute ketamine intoxication.
Prisotnost metoksetamina, uporabljenega samostojno ali v kombinaciji z drugimi snovmi, je bila ugotovljena pri 20 primerih zastrupitev brez smrtnega izida, o katerih je poročalo pet držav članic.
Twenty deaths associated with methoxetamine have been reported by six Member States that detected the substance in post-mortem samples.
Od novembra 2010 je o prisotnosti metoksetamina poleg Turčije in Norveške poročalo 23 držav članic.
Used alone or in combination with other substances, methoxetamine was detected in 20 non-fatal intoxications reported by five Member States.
Na podlagi informacij je mogoče sklepati, da se metoksetamin prodaja in uporablja kot samostojna snov, spletni trgovci na drobno, specializirane trgovine in ulični preprodajalci pa ga prodajajo tudi kot „zakonit“ nadomestek za ketamin.
Twenty-three Member States, Turkey and Norway have reported that they reported detection of methoxetamine, since November 2010.
V Uniji je bilo zaseženih več kilogramov metoksetamina v obliki prahu, vendar informacij o morebitni vpletenosti organiziranega kriminala ni.
Information suggests that it is sold and used as a substance in its own right, and that it is also sold as a ‘legal’ replacement for ketamine by internet retailers, ‘head shops’ and street-level drug dealers.
Za proizvodnjo metoksetamina ni potrebna specializirana oprema.
Multi-kilogram quantities in powder form have been seized within the Union, but there is no information on the possible involvement of organised crime.
Podatki o razširjenosti uporabe so omejeni na študije iz dveh držav članic, opravljene na podlagi nereprezentativnih vzorcev.
The manufacture of methoxetamine does not require sophisticated equipment.
Te študije kažejo, da je razširjenost uporabe metoksetamina v primerjavi s ketaminom manjša.
Prevalence data are limited to non-representative studies in two Member States.
Razpoložljive informacije kažejo, da se ta nova psihoaktivna snov lahko uživa v najrazličnejših okoljih, na primer doma, v barih, nočnih klubih in na glasbenih festivalih.
Those studies suggest that the prevalence of the use of methoxetamine is lower than that of ketamine.
Poročilo o oceni tveganja navaja, da bi bilo treba opraviti nadaljnje raziskave za določitev zdravstvenih in socialnih tveganj, ki jih povzroča metoksetamin.
The available information suggests that it may be consumed in a wide range of settings, including at home, in bars, in nightclubs and at music festivals.
Vendar razpoložljivi dokazi in informacije zagotavljajo zadostno podlago za uvedbo nadzornih ukrepov za metoksetamin po vsej Uniji.
The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by methoxetamine.
Zaradi zdravstvenih tveganj, ki jih povzroča metoksetamin, kakor so bila dokumentirana ob ugotovitvi njegove prisotnosti pri več zabeleženih smrtnih primerih, zaradi dejstva, da ga lahko uporabniki zaužijejo nevede, in zaradi pomanjkanja njegove zdravstvene vrednosti ali uporabe, bi bilo treba za metoksetamin uvesti nadzorne ukrepe po vsej Uniji.
However, the available evidence and information provides sufficient grounds for subjecting methoxetamine to control measures across the Union.
Ker je v devetih državah članicah uveden nadzor za metoksetamin na podlagi nacionalne zakonodaje, ki je usklajena z obveznostmi iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971, devet držav članic pa nadzor izvaja z drugimi zakonodajnimi ukrepi, bi uvedba nadzornih ukrepov za to snov po vsej Uniji pripomogla k preprečevanju nastanka ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter bi zagotovila zaščito pred tveganji, ki lahko izhajajo iz razpoložljivosti in uporabe te snovi.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, methoxetamine should be subjected to control measures across the Union.
Sklep 2005/387/PNZ pridržuje Svetu izvedbena pooblastila, da bi se bilo mogoče na ravni Unije z uvedbo nadzornih ukrepov po vsej Uniji za nove psihoaktivne snovi hitro in strokovno odzvati na njihov pojav, ki ga države članice ugotovijo in o njem poročajo.
Given that nine Member States control methoxetamine under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances and nine Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
Pogoji za izvrševanje teh izvedbenih pooblastil so bili izpolnjeni in postopki upoštevani, zato bi bilo treba sprejeti izvedbeni sklep za uvedbo nadzornih ukrepov za 25I-NBOMe, AH-7921, MDPV in metoksetamin v celotni Uniji.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Sodišče Evropske unije je v sodbah z dne 16. aprila 2015 v združenih zadevah C-317/13 in C-679/13 [3] ugotovilo, da bi se moral Svet pred sprejetjem izvedbenih sklepov na podlagi člena 8(3) Sklepa 2005/387/PNZ posvetovati z Evropskim parlamentom.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 25I-NBOMe, AH-7921, MDPV and methoxetamine under control across the Union.
Izvedbeni sklep Sveta 2014/688/EU [4] je bil sprejet brez takšnega predhodnega posvetovanja, zato je bila storjena postopkovna napaka.
In its judgment of 16 April 2015 in Joined Cases C-317/13 and C-679/13 [3], the Court of Justice of the European Union held that prior to adopting an implementing decision on the basis of Article 8(3) of Decision 2005/387/JHA, the Council should consult the European Parliament.
Zato bi bilo treba Sklep 2014/688/EU nadomestiti s tem sklepom.
Council Implementing Decision 2014/688/EU [4] was adopted without such prior consultation and consequently is vitiated by a procedural defect.
Zaradi neprekinjene veljavnosti nadzornih ukrepov za 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921), 3,4-metilendioksipirovaleron (MDPV) in 2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin) po vsej Uniji in zaradi izpolnjevanja obveznosti držav članic iz Konvencije Združenih narodov o psihotropnih snoveh iz leta 1971 in Enotne konvencije Združenih narodov o mamilih iz leta 1961, ta sklep ne sme posegati v obveznosti držav članic v zvezi z roki za uvedbo nadzornih ukrepov in kazenskih sankcij za navedene nove psihoaktivne snovi v nacionalno zakonodajo, kot je določeno v členu 2 Sklepa 2014/688/EU.
Decision 2014/688/EU should, therefore, be replaced by this Decision.
Sklep 2005/387/PNZ je za Dansko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
In order to ensure the continuity of control measures across the Union, as well as of the compliance with the obligations of the Member States under the 1971 United Nations Convention on Psychotropic Substances and under the 1961 United Nations Single Convention on Narcotic Drugs with regard to 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting those new psychoactive substances to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Sklep 2005/387/PNZ je za Irsko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.
HAS ADOPTED THIS DECISION:
Nadzorni ukrepi po vsej Uniji se uvedejo za naslednje nove psihoaktivne snovi:
Article 1
odo-2,5-dimetoksi-N-(2- metoksibenzil)fenetilamin (25I-NBOMe);
The following new psychoactive substances shall be subjected to control measures across the Union:
3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921);
odo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe);
3,4-metilendioksipirovaleron (MDPV);
3,4-dichloro-N-[[1-dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);
2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin).
3,4-methylenedioxypyrovalerone (MDPV);
Člen 2
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine).
Sklep 2014/688/EU se nadomesti brez poseganja v obveznosti držav članic v zvezi z roki za uvedbo nadzornih ukrepov in kazenskih sankcij za 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921), 3,4-metilendioksipirovaleron (MDPV) in 2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin) v nacionalno zakonodajo, kot je določeno v členu 2 Sklepa 2014/688/EU.
Decision 2014/688/EU is replaced, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Ta sklep začne veljati dan po objavi v Uradnem listu Evropske unije.
The President
Sklep Sveta 2003/847/PNZ z dne 27. novembra 2003 o ukrepih nadzora in kazenskih sankcijah glede novih sintetičnih drog 2C-1, 2C-T-2, 2C-T-7 in TMA-2 (UL L 321, 6.12.2003, str. 64).
OJ L 127, 20.5.2005, p. 32.
Sodba Sodišča z dne 16. aprila 2015, Evropski parlament proti Svetu Evropske unije, združeni zadevi C-317/13 in C-679/13, ECLI:EU:C:2015:223.
Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2 (OJ L 321, 6.12.2003, p. 64).
Izvedbeni sklep Sveta 2014/688/EU z dne 25. septembra 2014 o uvedbi nadzornih ukrepov za 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921), 3,4-metilendioksipirovaleron (MDPV) in 2-(3-metoksifenil)-2-(etilamino)cikloheksanon (metoksetamin) (UL L 287, 1.10.2014, str. 22).
Judgment of the Court of Justice of 16 April 2015, Parliament v Council, Joined Cases C-317/13 and C-679/13, ECLI:EU:C:2015:223.
Glede na navedbe uporabnikov so učinki AH-7921 podobni učinkom klasičnih opioidov, npr. občutek blage evforije, srbečice in sprostitve; zdi se, da je slabost tipičen škodljiv učinek.
Council Implementing Decision (EU) 2015/1876
Izvedbeni sklep Sveta (EU) 2015/1876
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk-assessment and control of new psychoactive substances [1], and in particular Article 8(3) thereof,
ob upoštevanju Sklepa Sveta 2005/387/PNZ z dne 10. maja 2005 o izmenjavi podatkov, oceni tveganja in nadzoru nad novimi psihoaktivnimi snovmi [1] ter zlasti člena 8(3) Sklepa,
A Risk Assessment Report on the new psychoactive substance 5-(2-aminopropyl)indole was drawn up in accordance with Article 6 of Decision 2005/387/JHA by the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) during a special session, and was subsequently submitted to the Commission and to the Council on 16 April 2013.
Poročilo o oceni tveganja glede nove psihoaktivne snovi 5-(2-aminopropil)indola je v skladu s členom 6 Sklepa 2005/387/PNZ oblikoval znanstveni odbor Evropskega centra za spremljanje drog in zasvojenosti z drogami (EMCDDA) na posebni seji ter je bilo nato 16. aprila 2013 predloženo Komisiji in Svetu.
The substance 5-(2-aminopropyl)indole is a synthetic derivative of indole substituted at the phenyl side of the indole ring system.
Snov 5-(2-aminopropil)indol je sintetični derivat indola, substituiran na fenilnem delu indolovih obročev.
It is commercially available on the internet and from ‘head shops’, marketed as a ‘research chemical’.
Naprodaj je prek interneta in v trgovinah, specializiranih za prodajo izdelkov, povezanih z uživanjem drog, kjer ga tržijo kot kemikalijo za raziskave.
It has also been detected in samples of a product sold as a ‘legal high’ called ‘Benzo Fury’, and in tablets resembling ecstasy.
Ugotovljen je bil tudi v vzorcih izdelka z imenom „Benzo Fury“, ki se prodaja kot neprepovedana spletna droga, in v tabletah, podobnih ekstaziju.
The existing information and data suggest that the acute toxicity of 5-(2-aminopropyl)indole can provoke adverse effects in humans, such as tachycardia and hyperthermia, and may also cause mydriasis, agitation and tremor.
Po obstoječih informacijah in podatkih lahko akutna toksičnost 5-(2-aminopropil)indola pri človeku povzroči škodljive učinke, kot sta tahikardija in hipertermija, lahko pa povzroči tudi midriazo, tresenje in tremor.
5-(2-aminopropyl)indole may interact with other substances, including medical products and stimulants that act on the monoaminergic system.
Mogoče so interakcije med 5-(2-aminopropil)indolom in drugimi snovmi, vključno z medicinskimi proizvodi in poživili, ki delujejo na monoaminergični sistem.
The specific physical effects of 5-(2-aminopropyl)indole in humans are difficult to determine because there are no published studies assessing its acute and chronic toxicity, its psychological and behavioural effects, or dependence potential, and because of the limited information and data available.
Posebne fizične učinke 5-(2-aminopropil)indola pri človeku je težko določiti, saj ni objavljenih študij, ki bi ocenjevale njegovo akutno in kronično toksičnost, njegove psihične in vedenjske učinke ali možnosti za povzročanje odvisnosti in ker so na voljo le omejene informacije in podatki.
While it is not possible to determine with certainty the role of 5-(2-aminopropyl)indole in all of the fatalities, in some cases it has been specifically noted in the cause of death.
Čeprav ni mogoče z gotovostjo določiti vloge 5-(2-aminopropil)indola pri vseh smrtnih primerih, je bil ta v nekaterih primerih izrecno naveden kot vzrok smrti.
If this new psychoactive substance were to become more widely available and used, the implications for individual and public health could be significant.
Če bi ta nova psihoaktivna snov postala dostopnejša in bi se število njenih uporabnikov povečalo, bi to lahko imelo resne posledice za zdravje posameznikov in javno zdravje.
There is no information available on the social risks posed by 5-(2-aminopropyl)indole.
Informacije o socialnih tveganjih zaradi 5-(2-aminopropil)indola niso na voljo.
Nine European countries have reported to the EMCDDA and to the European Police Office (Europol) that they reported detection of 5-(2-aminopropyl)indole.
Devet evropskih držav je poročalo EMCDDA ter Evropskemu policijskemu uradu (Europol) o odkritjih 5-(2-aminopropil)indola.
No prevalence data is available on the use of 5-(2-aminopropyl)indole, but the limited information that exists suggests that it may be consumed in similar environments as other stimulants, such as in the home, in bars and nightclubs or at music festivals.
Ni podatkov o razširjenosti uporabe 5-(2-aminopropil)indola, vendar se po obstoječih omejenih informacijah verjetno uživa v podobnih okoljih kot druga poživila, na primer doma, v barih in nočnih klubih ter na glasbenih festivalih.
There is no information that suggests that 5-(2-aminopropyl)indole is manufactured in the Union, and there is no evidence suggesting the involvement of organised crime in the manufacture, distribution or supply of this new psychoactive substance.
Ni informacij, da se 5-(2-aminopropil)indol proizvaja v Uniji, prav tako ni dokazov, da bi bil v proizvodnjo, distribucijo ali dobavo te nove psihoaktivne snovi vpleten organizirani kriminal.
The substance 5-(2-aminopropyl)indole has no known, established or acknowledged medical value or use, and there is no marketing authorisation covering this new psychoactive substance in the Union.
Snov 5-(2-aminopropil)indol nima znane, dokazane ali priznane zdravstvene vrednosti ali uporabe, prav tako pa v Uniji te nove psihoaktivne snovi ne zajema nobeno dovoljenje za promet z zdravilom.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it is being used for other purposes.
Ni znakov, da bi se uporabljala še v druge namene poleg uporabe kot analitični referenčni standard in pri znanstvenih raziskavah.
The substance 5-(2-aminopropyl)indole has not been, nor is it currently, under assessment by the United Nations' system, as defined in Decision 2005/387/JHA.
Snov 5-(2-aminopropil)indol še ni bila in ni v postopku ocenjevanja v sistemu Združenih narodov, kot je določeno v Sklepu 2005/387/PNZ.
Five European countries apply national legislation on new psychoactive substances, dangerous goods or medicines to control 5-(2-aminopropyl)indole.
Vendar so že razpoložljivi dokazi in informacije zadostna podlaga za uvedbo nadzornih ukrepov za 5-(2-aminopropil)indol v vsej Uniji.
The Risk Assessment Report reveals that there is limited scientific evidence available on 5-(2-aminopropyl)indole and points out that further research would be needed to determine the health and social risks that it poses.
Zaradi zdravstvenih tveganj zaradi 5-(2-aminopropil)indola, kar je dokumentirano ob ugotovitvi njegove prisotnosti pri več zabeleženih smrtnih primerih, zaradi dejstva, da ga lahko uporabniki zaužijejo nevede, in zaradi pomanjkanja njegove medicinske vrednosti ali uporabe, bi bilo treba za 5-(2-aminopropil)indol uvesti nadzorne ukrepe v vsej Uniji.
However, the available evidence and information provides sufficient ground for subjecting 5-(2-aminopropyl)indole to control measures across the Union.
Ker šest držav članic z raznimi vrstami zakonodaje že nadzira 5-(2-aminopropil)indol, bi uvedba nadzornih ukrepov za to snov v vsej Uniji prispevala k preprečevanju nastajanja ovir v čezmejnem sodelovanju na področju kazenskega pregona in pravosodja ter bi uporabnike zaščitila pred tveganji, ki jih lahko povzroči uživanje te snovi.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, 5-(2-aminopropyl)indole should be subjected to control measures across the Union.
Sklep 2005/387/PNZ Svetu podeljuje izvedbena pooblastila, da bi se bilo mogoče na ravni Unije hitro in strokovno z uvedbo nadzornih ukrepov po vsej Uniji za nove psihoaktivne snovi odzvati na njihov pojav, ki ga države članice ugotovijo in o njem poročajo.
Given that six Member States already control 5-(2-aminopropyl)indole by means of different types of legislative provisions, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and protect users from the risks that its consumption can pose.
Pogoji za izvrševanje teh izvedbenih pooblastil so bili izpolnjeni in postopki upoštevani, zato bi bilo treba sprejeti izvedbeni sklep za uvedbo nadzornih ukrepov za 5-(2-aminopropil)indol v vsej Uniji.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Ta sklep nadomešča izvedbeni sklep Sveta 2013/496/EU [2], ki ga je Sodišče Evropske unije (v nadaljnjem besedilu: Sodišče) razglasilo za ničnega v sodbi z dne 16. aprila 2015 v Zadevi C-679/13 [3].
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 5-(2-aminopropyl)indole under control across the Union.
V tej sodbi je Sodišče odločilo, da se učinki Sklepa 2013/496/EU ohranijo v veljavi do začetka veljavnosti novih aktov, s katerimi bodo nadomeščeni stari.
This Decision replaces Council Implementing Decision 2013/496/EU [2] which was annulled by the Court of Justice of the European Union (‘the Court’) by its judgment of 16 April 2015 in Case C-679/13 [3].
Zato Sklep 2013/496/EU preneha učinkovati z začetkom veljavnosti tega sklepa.
In that judgment, the Court maintained the effects of Decision 2013/496/EU until the entry into force of new acts intended to replace it.
Zaradi neprekinjene veljavnosti nadzornih ukrepov za 5-(2-aminopropil)indol po vsej Uniji ta sklep ne sme posegati v obveznosti držav članic v zvezi z roki za uvedbo nadzornih ukrepov in kazenskih sankcij za navedeno novo psihoaktivno snovjo v nacionalno zakonodajo, kot je določeno v členu 2 Sklepa 2013/496/EU.
Therefore, as of the day of entry into force of this Decision, Decision 2013/496/EU ceases to produce effects.
Sklep 2005/387/PNZ je za Dansko zavezujoč, zato sodeluje pri sprejetju in uporabi tega sklepa, s katerim se izvaja Sklep 2005/387/PNZ.